Arena Pharmaceuticals (ARNA) Shares are Down -3.68%

Arena Pharmaceuticals (ARNA) : During the past 4 weeks, traders have been relatively bearish on Arena Pharmaceuticals (ARNA), hence the stock is down -9.65% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -4.16% relative to the S&P 500. The 4-week change in the price of the stock is -9.77% and the stock has fallen -3.68% in the past 1 week.

The stock has recorded a 20-day Moving Average of 4.15% and the 50-Day Moving Average is 5.93%.The 200 Day SMA reached 9.48%. Arena Pharmaceuticals, Inc. has dropped 21.89% during the last 3-month period . Year-to-Date the stock performance stands at -17.37%.


Arena Pharmaceuticals (NASDAQ:ARNA): After opening at $1.58, the stock dipped to an intraday low of $1.56 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $1.59 and the buying power remained strong till the end. The stock closed at $1.57 for the day, a gain of 0.64% for the day session. The total traded volume was 876,867. The stocks close on the previous trading day was $1.56.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors (GPCRs). The Companys drug, BELVIQ (lorcaserin HCl), was approved by the United States Food and Drug Administration for marketing in the United States. In addition to BELVIQ, the Company has other drug candidates and compounds at various stages of research and development. The Company is exploring lorcaserins once-a-day, extended release formulation, as an aid to smoking cessation, in combination with phentermine and other agents for weight management, and for other possible indications. The Companys other drug candidates include ralinepag for vascular diseases, APD334 for autoimmune diseases, APD371 for pain and fibrotic diseases, and temanogrel for thrombotic diseases.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.